Bryan Supran Biography and Net Worth

Chief Legal Officer of Alnylam Pharmaceuticals

Bryan Supran joined Alnylam as Chief Legal Officer in September 2025. He brings over 25 years of legal leadership experience in the life sciences and pharmaceutical sectors. Most recently, Bryan served as Senior Vice President and Deputy General Counsel at Pfizer, where he led high-performing teams and provided strategic counsel across major corporate, transactional, intellectual property, regulatory, litigation, and international matters. His role included counseling management and the Board of Directors on strategic initiatives and business development transactions, such as Pfizer’s COVID-19 vaccine collaboration with BioNTech SE, the successful split-off of its animal health business as Zoetis Inc., and the joint venture with GSK to create Haleon, where he served on the Board of Directors from 2018 to 2025.

Before Pfizer, Bryan was chief securities, corporate governance, and transactional counsel at Wyeth, playing a key role in negotiating and executing its merger with Pfizer. He began his legal career at Ropes & Gray LLP in Boston and New York, where he helped establish the firm’s life sciences practice. Bryan holds a J.D. from New York University School of Law and a B.A. in Politics and East Asian Studies from Princeton University.

What is Bryan Supran's net worth?: The estimated net worth of Bryan Supran is at least $2.87 million as of October 2nd, 2026. Mr. Supran owns 12,807 shares of Alnylam Pharmaceuticals stock worth more than $2,868,000 as of October 7th. This net worth evaluation does not reflect any other investments that Mr. Supran may own. Learn More about Bryan Supran's net worth.
How do I contact Bryan Supran?: The corporate mailing address for Mr. Supran and other Alnylam Pharmaceuticals executives is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. Alnylam Pharmaceuticals can also be reached via phone at (617) 551-8200 and via email at [email protected]. Learn More on Bryan Supran's contact information.
Has Bryan Supran been buying or selling shares of Alnylam Pharmaceuticals?: Within the last three months, Bryan Supran has sold $398,855.04 in Alnylam Pharmaceuticals stock. Most recently, Bryan Supran sold 1,758 shares of the business's stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $226.88, for a transaction totalling $398,855.04. Following the completion of the sale, the executive vice president now directly owns 12,807 shares of the company's stock, valued at $2,905,652.16. Learn More on Bryan Supran's trading history.
Who are Alnylam Pharmaceuticals' active insiders?: Alnylam Pharmaceuticals' insider roster includes Dennis Ausiello (Director), Michael Bonney (Director), Jeffrey Dunn (CEO), Kevin Fitzgerald (EVP), Indrani Franchini (EVP), Pushkal Garg (CMO), Yvonne Greenstreet (COO), Laurie Keating (EVP), John Maraganore (CEO), Melissa McLaughlin (Chief Human Resources Officer), Steven Paul (Director), Jeffrey Poulton (CFO), David Pyott (Director), Colleen Reitan (Director), Amy Schulman (Director), Phillip Sharp (Director), Bryan Supran (Chief Legal Officer), Tolga Tanguler (EVP), and Akshay Vaishnaw (Insider). Learn More on Alnylam Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Alnylam Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 26 times. They sold a total of 101,199 shares worth more than $37,988,143.37. The most recent insider tranaction occured on October, 2nd when EVP Bryan Supran sold 1,758 shares worth more than $398,855.04. Insiders at Alnylam Pharmaceuticals own 0.9% of the company. Learn More about insider trades at Alnylam Pharmaceuticals.
Information on this page was last updated on 10/2/2026.

Bryan Supran Insider Trading History at Alnylam Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/2/2026	Sell	1,758	$226.88	$398,855.04	12,807

Bryan Supran Buying and Selling Activity at Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Company Overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $223.94

$217.18

$229.18

50 Day Range

MA: $238.92

$205.48

$286.62

2 Week Range

Now: $223.94

$197.81

$495.55

Volume

1,356,263 shs

Average Volume

1,387,619 shs

Market Capitalization

$29.97 billion

P/E Ratio

41.62

Dividend Yield

N/A

Beta

0.28